Breast Cancer vs Fibroadenoma

Why Lymphedema of the arm is correct

• Axillary lymph node dissection disrupts lymphatic drainage of the ipsilateral arm, and adding regional radiation compounds the injury, making lymphedema the highest-yield complication of this surgery-plus-radiation combination.
• It classically presents months to years later as painless, progressive, nonpitting swelling of the ipsilateral arm and hand without the erythema, warmth, or tenderness that would suggest cellulitis or DVT, matching this patient's picture.
• Risk is greatest with axillary dissection plus radiation; sentinel lymph node biopsy alone carries a much lower risk.

Why the others are wrong

• Post-radiation fibrosis — radiation injury to the chest wall and axilla produces firm induration, skin thickening, and restricted shoulder motion rather than the gradual painless swelling of the entire arm and hand described here.
• Recurrent axillary tumor — nodal recurrence usually declares itself with a palpable axillary mass or brachial plexus involvement (pain, numbness, weakness) and is far less common than lymphedema at this interval; her swelling is painless and neurologically silent.
• Axillary vein thrombosis — venous obstruction causes acute-onset pitting edema with cyanosis, dilated superficial collateral veins, and discomfort, not slowly progressive nonpitting swelling over months.

Why Reassurance with routine clinical follow-up is correct

• Her exam, ultrasound (oval, circumscribed, parallel, hypoechoic) and core biopsy all agree on a simple fibroadenoma. It is benign, does not raise her breast cancer risk, and often stays stable or shrinks over time.
• The ASBrS/SBI 2025 guideline (Rosenberger et al., JAMA Surg 2025) says fibroadenomas proven by a concordant core biopsy do not need imaging follow-up. She can return to age-appropriate screening and needs new imaging only if the mass grows, becomes symptomatic or changes on exam.
• She has none of the guideline's reasons for removal (symptoms, patient preference, large size or substantive growth), so reassurance with routine clinical follow-up is the right first step.

Why the others are wrong

• Surgical excision of the breast lesion — Under ASBrS/SBI 2025, a concordant fibroadenoma without atypia is removed only if it causes symptoms, is large, is clearly growing, or the patient wants it out. Atypia on biopsy or a suspected phyllodes tumor also calls for excision. This stable 1.5-cm mass has none of these.
• Ultrasound-guided percutaneous cryoablation — This FDA-cleared minimally invasive treatment is an alternative to surgery for selected small fibroadenomas when the patient wants the lesion removed. A stable, asymptomatic, biopsy-proven fibroadenoma needs no treatment.
• Vacuum-assisted repeat core needle biopsy — Repeat sampling is for a nondiagnostic specimen or a mismatch between imaging and pathology (excision is the other option there). Features of phyllodes tumor, such as rapid growth or cellular stroma, call for excisional biopsy rather than another core. Her benign result fits the classic ultrasound appearance, so another biopsy adds nothing.

Additional high-yield points

• Know the two follow-up paths. A probably benign (BI-RADS 3) mass that is not biopsied gets short-interval ultrasound, first at about 6 months. A concordant benign core biopsy ends the need for imaging surveillance.
• Ultrasound is the first imaging test for a palpable breast mass in a woman under 30. Diagnostic mammography becomes an option from age 30 and is standard from 40.
• Complex fibroadenomas (cysts >3 mm, sclerosing adenosis, epithelial calcifications, papillary apocrine change) carry a modestly higher breast cancer risk. A fibroepithelial mass that grows quickly should be excised to rule out phyllodes tumor.